- HK$3.16bn
- HK$1.96bn
- CNY570.09m
Annual income statement for Medtide, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 351 | 337 | 442 | 570 |
| Cost of Revenue | ||||
| Gross Profit | 201 | 180 | 250 | 362 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 215 | 229 | 279 | 337 |
| Operating Profit | 136 | 108 | 163 | 234 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 67.6 | 62 | 78.4 | 251 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 54 | 48.9 | 59.2 | 217 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 54 | 48.9 | 59.2 | 217 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 54 | 48.9 | 59.2 | 217 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.385 | 0.349 | 0.556 | 1.65 |